Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Sjögren’s Disease

Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

Lara C. Pullen, PhD  |  June 12, 2017

The P2X7 receptor inflammasome axis may have a role in the pathogenesis of Sjögren’s syndrome and non-Hodgkin’s lymphoma. According to new research, patients with Sjögren’s syndrome who developed non-Hodgkin’s lymphoma had an increased expression of the P2X7R-inflammasome axis and the glandular expression of IL-18, suggesting a possible novel biomarker…

Sjögren’s Awareness Month: Educate Patients, Families, Caregivers

Richard Quinn  |  April 10, 2017

April is Sjögren’s Awareness Month, a time for rheumatologists to help educate the public and themselves about Sjögren’s syndrome and its diagnosis. With newly published clinical practice guidelines, Nancy Carteron, MD, encourages rheumatologists to be first responders for this patient population…

Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain

Arthritis Care & Research  |  April 2, 2017

The clinical practice guidelines for managing Sjögren’s syndrome, developed by the Sjögren’s Syndrome Foundation with the ACR, were designed to improve quality and consistency of care. In total, 19 recommendations were agreed on, which include managing the rheumatic and systemic aspects of the disease. Recommendations include a decision tree for the use of DMARDs for inflammatory musculoskeletal pain, use of self-care measures and exercise to reduce fatigue, and the use of rituximab in selected clinical settings for oral and ocular dryness…

Research Identifies Two New Cell Types in Sjögren’s Syndrome

Lara C. Pullen, PhD  |  January 9, 2017

Two previously unidentified cellular players in the pathogenesis of primary Sjogren’s syndrome (pSS) have been discovered: a regulatory T cell (Prdm1+eTreg) and a helper T cell (Il21+Th1). In the study, researchers also identified the transcriptional signatures of these cells and their differential dependency on the lymphotoxin/LIGHT signaling axis, which may guide future therapeutic interventions…

Location & Ethnicity Affect Manifestations of Primary Sjogren’s Syndrome

Marilynn Larkin  |  December 12, 2016

NEW YORK (Reuters Health)—Geolocation and ethnicity exert a “strong influence” on the phenotype of primary Sjogren’s syndrome, researchers report. “The influence of ethnicity on the phenotypic expression of systemic autoimmune diseases has been suggested by various studies, especially in systemic lupus erythematosus, which has been reported as being more frequent and having less favorable outcomes…

ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome

Kathy Holliman  |  November 15, 2016

Classification criteria for primary Sjögren’s syndrome (SS) have been approved by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), validating an international set of classification criteria for SS using standards set by both organizations. Those criteria can now be found in the 2016 ACR/EULAR Classification Criteria for Primary Sjögren’s Syndrome: A…

Dysbiosis of Gut, But Not Ocular Microbiome, Associated with Sjögren’s Syndrome

Lara C. Pullen, PhD  |  July 11, 2016

Research has explored the connection between Sjögren’s syndrome and intestinal dysbiosis associated with ocular mucosal disease. A recent study found that oral antibiotics and desiccating stress lead to extreme changes in the gut microbiota in mice. In patients with Sjögren’s syndrome, researchers found that patients with the most severe keratoconjunctivitis sicca and combined systemic and ocular disease had the lowest diversity of stool microbiota…

A Healthy Skepticism: Researchers Evaluate CNS Manifestations of Rheumatic Disease

Thomas R. Collins  |  December 22, 2015

SAN FRANCISCO—Let’s say your radiologist comes to you and says that an angiogram gives a diagnosis of CNS vasculitis on four patients, all with acute onset of headache and stroke: One is a 25-year-old woman who is three months pregnant. Another is a 50-year-old man using excessive doses of nasal decongestants. Another is a 40-year-old…

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

Robert I. Fox, MD, PhD, & Carla M. Fox, RN  |  November 17, 2015

Despite a generation of advances in molecular biology, a huge gap exists between the Sjögren’s syndrome (SS) patient’s description of their symptoms and the objective findings. Current issues include: Many SS patients are misclassified as either rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), even within rheumatology clinics. Frequently, the sickest SS patients with extraglandular…

2014 ACR/ARHP Annual Meeting: Sjögren’s Complications

Susan Bernstein  |  April 1, 2015

Tips to screen for, treat central or peripheral nervous system disorders, lymphoma in patients with Sjögren’s syndrome

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences